Early phase studies can be complex, especially if you receive last-minute requests for supplemental studies from the FDA. Taking a proactive approach is ideal. But there is a chance you’ll be required to submit results for certain studies you may not have originally considered when mapping out your clinical development program. It’s crucial to anticipate what these possible requests might be so you can avoid delays.